Narayana Hrudayalaya working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

31.87×	31.87×	35.37×	30.85×	23.87×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
27.99×	27.99×	32.53×	31.03×	35.02×
193.39×	193.39×	189.19×	207.08×	224.22×
−133.53×	−133.53×	−121.29×	−145.20×	−165.33×
4.19×	3.75×	4.04×	6.00×	14.75×
0.80×	0.80×	0.85×	1.03×	1.24×
2.01×	2.01×	1.25×	1.35×	1.79×
1.00×	1.00×	0.78×	0.93×	1.12×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

NH₹1,714.50

Narayana Hrudayalaya Ltd.

· Pharma & Health

₹ CrorePeersAPOLLOHOSP MAXHEALTH FORTIS NEULANDLAB NATCOPHARM LALPATHLAB SAILIFE COHANCEMcap ₹35,038 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Inventory Days (DIO)	23.87	30.85	35.37	31.87	31.87
Receivable Days (DSO)	35.02	31.03	32.53	27.99	27.99
Payable Days (DPO)	224.22	207.08	189.19	193.39	193.39
Cash Conversion Cycle (days)	-165.33	-145.20	-121.29	-133.53	-133.53
Working Capital Turnover	14.75	6.00	4.04	3.75	4.19
Asset Turnover	1.24	1.03	0.85	0.80	0.80
Cash Conversion (CFO/Net Income)	1.79	1.35	1.25	2.01	2.01
CFO/EBITDA	1.12	0.93	0.78	1.00	1.00

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.